Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1089/adt.2021.090 http://scihub22266oqcxt.onion/10.1089/adt.2021.090 34990284!ä!34990284 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Assay+Drug+Dev+Technol 2022 ; 20 (1): 55-62 Nephropedia Template TP {{tp|p=34990284|t=2022. Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role |pdf=|usr=}}{{34990284}} gab.com Text Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role JO: Assay Drug Dev Technol http://www.kidney.de/pget.php?&tw=1&pmid=34990284 #FOAvip Cytokine release syndrome, a prominent mechanism of morbidity and mortality in patients with coronavirus disease 2019 (COVID-19), can cause multiple bodily reactions, including excessive release of proinflammatory mediators, with tumor necrosis factor-alpha (TNF-alpha) being the most prevalent cytokine combined with persistently elevated D-dimer levels that are indicative of potential thrombotic events, low levels of endogenous nitric oxide (NO) generation, and progressive decrease in hemoglobin production. In our argument, the conceptual repurposing of hydroxyurea (HU) for managing COVID-19 can provide a promising therapeutic option originating from a rich history of investigational antiviral activity. HU as a proposed supportive therapeutic agent for treating COVID-19 can exemplify a successful remedial choice through its anti-inflammatory activity along with an intrinsic propensity to control the circulatory levels of key cytokines including TNF-alpha. HU has the ability to undergo in vivo NO conversion acting as NO donor together with being a prominent inducer of fetal hemoglobin (HbF) production. The combination of the mentioned two properties allows HU to possess evident capability of protecting against thrombotic events by controlling D-dimer levels. The implication of our hypothetical argument sheds light on the curative potential of HU, which can be strategically harnessed against COVID-19. Twit Text FOAVip Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role ????Assay Drug Dev Technol http://www.kidney.de/pget.php?&tw=1&pmid=34990284 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34990284 #FOAvip English Wikipedia <ref>{{Cite pmid|34990284}}</ref> Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role #MMPMID34990284 Ben Moftah M; Eswayah A Assay Drug Dev Technol 2022[Jan]; 20 (1): 55-62 PMID34990284show ga Cytokine release syndrome, a prominent mechanism of morbidity and mortality in patients with coronavirus disease 2019 (COVID-19), can cause multiple bodily reactions, including excessive release of proinflammatory mediators, with tumor necrosis factor-alpha (TNF-alpha) being the most prevalent cytokine combined with persistently elevated D-dimer levels that are indicative of potential thrombotic events, low levels of endogenous nitric oxide (NO) generation, and progressive decrease in hemoglobin production. In our argument, the conceptual repurposing of hydroxyurea (HU) for managing COVID-19 can provide a promising therapeutic option originating from a rich history of investigational antiviral activity. HU as a proposed supportive therapeutic agent for treating COVID-19 can exemplify a successful remedial choice through its anti-inflammatory activity along with an intrinsic propensity to control the circulatory levels of key cytokines including TNF-alpha. HU has the ability to undergo in vivo NO conversion acting as NO donor together with being a prominent inducer of fetal hemoglobin (HbF) production. The combination of the mentioned two properties allows HU to possess evident capability of protecting against thrombotic events by controlling D-dimer levels. The implication of our hypothetical argument sheds light on the curative potential of HU, which can be strategically harnessed against COVID-19. |*COVID-19[MESH] |*Hydroxyurea/pharmacology[MESH] |Cytokine Release Syndrome[MESH] |Cytokines[MESH] |Humans[MESH]Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulat(epmc).pdf DeepDyve Pubget Overpricing